Nusinersen versus sham control in later-onset spinal muscular atrophy

Nusinersen versus sham control in later-onset spinal muscular atrophy

<p><strong>Background:</strong><br /> Nusinersen is an antisense oligonucleotide drug that modulates pre–messenger RNA splicing of the survival motor neuron 2 (SMN2) gene. It has been developed for the treatment of spinal muscular atrophy (SMA).</p><br /> <p&g...

Detaylı Bibliyografya
Asıl Yazarlar:	Mercuri, E, Darras, BT, Chiriboga, CA, Day, JW, Campbell, C, Connolly, AM, Iannaccone, ST, Kirschner, J, Kuntz, NL, Saito, K, Shieh, PB, Tulinius, M, Mazzone, ES, Montes, J, Bishop, KM, Yang, Q, Foster, R, Gheuens, S, Bennett, CF, Farwell, W, Schneider, E, De Vivo, DC, Finkel, RS
Materyal Türü:	Journal article
Dil:	English
Baskı/Yayın Bilgisi:	Massachusetts Medical Society 2018

Benzer Materyaller

Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy
Yazar:: Finkel, RS, ve diğerleri
Baskı/Yayın Bilgisi: (2017)

Scientific rationale for a higher dose of nusinersen
Yazar:: Richard S. Finkel, ve diğerleri
Baskı/Yayın Bilgisi: (2022-06-01)

Nusinersen in pediatric and adult patients with type III spinal muscular atrophy
Yazar:: Maria Carmela Pera, ve diğerleri
Baskı/Yayın Bilgisi: (2021-08-01)

Motor function in type 2 and 3 SMA patients treated with Nusinersen: a critical review and meta-analysis
Yazar:: Giorgia Coratti, ve diğerleri
Baskı/Yayın Bilgisi: (2021-10-01)

RESTORE: a prospective multinational registry of patients with genetically confirmed spinal muscular atrophy - rationale and study design
Yazar:: Finkel, RS, ve diğerleri
Baskı/Yayın Bilgisi: (2020)

Effectiveness of Nusinersen in Adolescents and Adults with Spinal Muscular Atrophy: Systematic Review and Meta-analysis
Yazar:: Tim Hagenacker, ve diğerleri
Baskı/Yayın Bilgisi: (2024-09-01)

Experiences of caregivers of children with spinal muscular atrophy participating in the expanded access program for nusinersen: a longitudinal qualitative study
Yazar:: Petra Kiefer, ve diğerleri
Baskı/Yayın Bilgisi: (2020-07-01)

Patients’ Perceptions of Nusinersen Effects According to Their Responder Status
Yazar:: Lilien, C, ve diğerleri
Baskı/Yayın Bilgisi: (2024)

Nusinersen and spinal muscular atrophies: Where are we in 2020?
Yazar:: Satish V Khadilkar, ve diğerleri
Baskı/Yayın Bilgisi: (2020-01-01)

Is “sham” stimulation really sham? Insights from a randomized, sham-controlled continuous theta-burst stimulation (cTBS) trial
Yazar:: Christopher Austelle, ve diğerleri
Baskı/Yayın Bilgisi: (2025-01-01)

The efficacy and safety of nusinersen within the expanded access program in Russia
Yazar:: S. B. Artemieva, ve diğerleri
Baskı/Yayın Bilgisi: (2020-12-01)

Nusinersen mitigates neuroinflammation in severe spinal muscular atrophy patients
Yazar:: Tommaso Nuzzo, ve diğerleri
Baskı/Yayın Bilgisi: (2023-02-01)

Response of plasma microRNAs to nusinersen treatment in patients with SMA
Yazar:: Irina T. Zaharieva, ve diğerleri
Baskı/Yayın Bilgisi: (2022-07-01)

Nusinersen efficacy data for 24‐month in type 2 and 3 spinal muscular atrophy
Yazar:: Marika Pane, ve diğerleri
Baskı/Yayın Bilgisi: (2022-03-01)

Type I SMA “new natural history”: long‐term data in nusinersen‐treated patients
Yazar:: Marika Pane, ve diğerleri
Baskı/Yayın Bilgisi: (2021-03-01)

Sitting in patients with spinal muscular atrophy type 1 treated with nusinersen
Yazar:: Aragon-Gawinska, K, ve diğerleri
Baskı/Yayın Bilgisi: (2019)

Nusinersen treatment of spinal muscular atrophy: current knowledge and existing gaps
Yazar:: Gidaro, T, ve diğerleri
Baskı/Yayın Bilgisi: (2018)

3097 Cerebral venous sinus thrombosis after intrathecal administration of nusinersen
Yazar:: Irene Tan, ve diğerleri
Baskı/Yayın Bilgisi: (2024-08-01)

Profiling neuroinflammatory markers and response to nusinersen in paediatric spinal muscular atrophy
Yazar:: Qiang Zhang, ve diğerleri
Baskı/Yayın Bilgisi: (2024-10-01)

Time-Efficacy in SMA Type 1 and 2 Cases Treated with Nusinersen
Yazar:: Mihaela Axente, ve diğerleri
Baskı/Yayın Bilgisi: (2023-06-01)

History of development of the life-saving drug “Nusinersen” in spinal muscular atrophy
Yazar:: Jiaying Qiu, ve diğerleri
Baskı/Yayın Bilgisi: (2022-08-01)

Physical Therapy and Nusinersen Impact on Spinal Muscular Atrophy Rehabilitative Outcome
Yazar:: Andrada Mirea, ve diğerleri
Baskı/Yayın Bilgisi: (2022-06-01)

Nusinersen in spinal muscular atrophy: Respiratory outcomes at tertiary care centers
Yazar:: Fahad Alsohime, ve diğerleri
Baskı/Yayın Bilgisi: (2020-01-01)

Safety and Efficacy of Nusinersen Focusing on Renal and Hematological Parameters in Spinal Muscular Atrophy
Yazar:: Hüseyin Bahadır Şenol, ve diğerleri
Baskı/Yayın Bilgisi: (2025-01-01)

Comprehensive Clinical Evaluation of Nusinersen Based on Multi-criteria Decision Analysis Method
Yazar:: QU Jinghan, ve diğerleri
Baskı/Yayın Bilgisi: (2024-06-01)

Nusinersen Wearing-Off in Adult 5q-Spinal Muscular Atrophy Patients
Yazar:: Alma Osmanovic, ve diğerleri
Baskı/Yayın Bilgisi: (2021-03-01)

Nusinersen Induces Disease-Severity-Specific Neurometabolic Effects in Spinal Muscular Atrophy
Yazar:: Francesco Errico, ve diğerleri
Baskı/Yayın Bilgisi: (2022-10-01)

Cognitive performance of adult patients with SMA before and after treatment initiation with nusinersen
Yazar:: Maximilian Vidovic, ve diğerleri
Baskı/Yayın Bilgisi: (2023-06-01)

Feasibility and safety of intrathecal treatment with nusinersen in adult patients with spinal muscular atrophy
Yazar:: Benjamin Stolte, ve diğerleri
Baskı/Yayın Bilgisi: (2018-10-01)

Cost effectiveness of nusinersen for patients with infantile-onset spinal muscular atrophy in US
Yazar:: Praveen Thokala, ve diğerleri
Baskı/Yayın Bilgisi: (2020-10-01)

Safety, Tolerability, and Effect of Nusinersen in Non-ambulatory Adults With Spinal Muscular Atrophy
Yazar:: Bakri Elsheikh, ve diğerleri
Baskı/Yayın Bilgisi: (2021-04-01)

Safety, Tolerability, and Effect of Nusinersen Treatment in Ambulatory Adults With 5q-SMA
Yazar:: Bakri Elsheikh, ve diğerleri
Baskı/Yayın Bilgisi: (2021-05-01)

Priority setting at the clinical level: the case of nusinersen and the Norwegian national expert group
Yazar:: Morten Magelssen, ve diğerleri
Baskı/Yayın Bilgisi: (2021-05-01)

Increased chitotriosidase 1 concentration following nusinersen treatment in spinal muscular atrophy
Yazar:: Maren Freigang, ve diğerleri
Baskı/Yayın Bilgisi: (2021-07-01)

Neurochemical markers in CSF of adolescent and adult SMA patients undergoing nusinersen treatment
Yazar:: Claudia D. Wurster, ve diğerleri
Baskı/Yayın Bilgisi: (2019-05-01)

Development and validation of an HILIC/MS/MS method for determination of nusinersen in rabbit plasma
Yazar:: Xiao Zhang, ve diğerleri
Baskı/Yayın Bilgisi: (2024-05-01)

Sham Transactions
Yazar:: Simpson, E
Baskı/Yayın Bilgisi: (2013)

Common complications in spinal muscular atrophy (SMA) type 1 after nusinersen treatment
Yazar:: Yiğithan Güzin, ve diğerleri
Baskı/Yayın Bilgisi: (2024-11-01)

Experience of Nusinersen in children with proximal spinal muscular atrophy 5q in Moscow region
Yazar:: M. V. Panteleeva
Baskı/Yayın Bilgisi: (2022-12-01)

Successful pregnancy of an SMA type 3 sitter on Nusinersen therapy - a case report
Yazar:: Miriam Hiebeler, ve diğerleri
Baskı/Yayın Bilgisi: (2025-01-01)